Ozempic was approved in 2017 as a once-weekly injection to manage blood sugar in type 2 diabetes. Nobody anticipated what would follow. Within a few years, clinical trials revealed that semaglutide — Ozempic’s active ingredient — produced weight loss of 15–17% of body weight, far beyond anything previously achievable with non-surgical treatment. Then came the next surprise: GLP-1 receptor agonists appear to reduce the risk of heart attacks, strokes, kidney disease, sleep apnoea, alcohol dependence, and now, according to emerging evidence, even Alzheimer’s disease. What began as a diabetes drug has become the most consequential class of pharmaceutical agents in a generation.
But as the science expands and the media hype intensifies, separating evidence from expectation matters enormously. This article does exactly that.
What Are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and — critically — sends satiety signals to the hypothalamus, the brain’s appetite control centre. GLP-1 receptor agonists are synthetic versions of this hormone, engineered to be more stable and longer-acting than the natural molecule.
The main agents in clinical use include semaglutide (Ozempic for diabetes, Wegovy for obesity — weekly injection; Rybelsus — oral tablet), tirzepatide (Mounjaro/Zepbound — a dual GIP and GLP-1 agonist achieving 22% weight loss in trials), and liraglutide (Victoza/Saxenda — daily injection, less commonly used). Oral semaglutide has made this class more accessible, though injectable forms remain more effective.
Beyond Diabetes and Weight Loss: The Expanding Evidence
Cardiovascular Protection
The SELECT trial (2023, NEJM) — the largest cardiovascular outcomes trial for an obesity drug — enrolled 17,604 overweight adults without diabetes and found that semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% over an average follow-up of 34 months. This was independent of weight loss, suggesting direct vascular effects. The FDA approved Wegovy for cardiovascular risk reduction in March 2024 — the first obesity drug ever to earn that indication.
Kidney Disease
The FLOW trial (2024, NEJM) showed semaglutide reduced the risk of serious kidney disease events by 24% in people with type 2 diabetes and CKD. Regulatory approval for kidney protection is underway.
Alcohol and Addiction
Multiple studies and case reports have documented remarkable reductions in alcohol consumption in people taking GLP-1 drugs — some reporting complete loss of desire to drink. JAMA published data in 2025 showing significant reductions in alcohol use disorder episodes in GLP-1 users. The mechanism appears to involve GLP-1 receptors in the brain’s reward circuitry — the same pathways targeted by addictive substances including alcohol, nicotine, and opioids.
Sleep Apnoea
The SURMOUNT-OSA trial (2024) showed tirzepatide reduced apnoea-hypopnoea index by up to 63% in obese patients with moderate-to-severe obstructive sleep apnoea — comparable to CPAP therapy in some subgroups. The FDA approved tirzepatide for sleep apnoea in June 2024.
Neurodegeneration
Observational data suggests people taking GLP-1 drugs have lower rates of Alzheimer’s disease and Parkinson’s disease than matched non-users. Randomised controlled trials of semaglutide for Alzheimer’s prevention are currently underway. The mechanism may involve GLP-1 receptors in the brain reducing neuroinflammation and amyloid accumulation — but this evidence remains preliminary.
The Access Crisis: A Drug for the Rich?
The most significant limitation of GLP-1 therapy is its cost. Semaglutide costs $900–$1,300 per month in the United States without insurance. In India, the branded version (Ozempic) costs approximately ₹10,000–₹15,000 per month. While domestic generic manufacturers — including Sun Pharma and Cipla — are developing biosimilar versions, none are yet approved for obesity indications at scale.
Furthermore, these drugs require lifelong use to sustain their benefits: weight regained within 12 months of stopping, and cardiovascular protection presumably lapses. For a global obesity epidemic affecting 2.5 billion people, a drug that costs over $10,000 per year per patient is not a public health solution without dramatic price reduction.
Who Should Take GLP-1 Drugs?
- Adults with type 2 diabetes — particularly those also needing cardiovascular or kidney protection
- Adults with BMI ≥30, or ≥27 with weight-related comorbidities (hypertension, sleep apnoea, fatty liver)
- Adults with established cardiovascular disease and overweight — given the SELECT trial evidence
- Not recommended for: pregnancy, personal or family history of medullary thyroid cancer, pancreatitis history — discuss with your doctor
Conclusion
GLP-1 receptor agonists may be the most medically significant drug class since statins. Their effects extend well beyond weight loss into cardiovascular, renal, neurological, and addiction medicine — effects that, if confirmed and replicated, make them candidates for the broadest disease prevention impact of any drug in modern history. The challenge now is equitable access: ensuring that this extraordinary science reaches not just wealthy patients in private clinics, but the billions of people for whom these drugs could prevent diabetes, heart attacks, kidney failure, and early death.
Sources: NEJM — SELECT Trial (2023) · NEJM — FLOW Trial (2024) · JAMA — GLP-1 and Alcohol Use (2025) · FDA Drug Approvals 2024 · The Lancet Diabetes & Endocrinology · SURMOUNT-OSA Trial (2024)
⚠️ Medical Disclaimer: GLP-1 drugs are prescription medications. Never start or stop them without medical supervision. This article is for educational purposes only. See our Medical Disclaimer.
Leave a Comment